Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of Teleflex Incorporated (NYSE:TFX – Get Rating) by 26.8% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 3,564 shares of the medical technology company's stock after acquiring an additional 753 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Teleflex were worth $876,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of the business. Ieq Capital LLC increased its holdings in Teleflex by 0.7% during the first quarter. Ieq Capital LLC now owns 6,088 shares of the medical technology company's stock valued at $2,160,000 after buying an additional 42 shares during the period. CIBC Asset Management Inc increased its holdings in Teleflex by 1.0% during the first quarter. CIBC Asset Management Inc now owns 4,471 shares of the medical technology company's stock valued at $1,586,000 after buying an additional 45 shares during the period. NorthCrest Asset Manangement LLC boosted its stake in Teleflex by 3.2% in the first quarter. NorthCrest Asset Manangement LLC now owns 1,620 shares of the medical technology company's stock valued at $575,000 after acquiring an additional 50 shares in the last quarter. Regentatlantic Capital LLC boosted its stake in Teleflex by 2.3% in the first quarter. Regentatlantic Capital LLC now owns 2,215 shares of the medical technology company's stock valued at $786,000 after acquiring an additional 50 shares in the last quarter. Finally, Guyasuta Investment Advisors Inc. boosted its stake in Teleflex by 1.8% in the first quarter. Guyasuta Investment Advisors Inc. now owns 2,810 shares of the medical technology company's stock valued at $997,000 after acquiring an additional 50 shares in the last quarter. 95.91% of the stock is owned by hedge funds and other institutional investors.
Get
Teleflex alerts:
Teleflex Trading Down 2.1 %
NYSE TFX opened at $207.48 on Friday. The company has a market capitalization of $9.73 billion, a PE ratio of 19.28, a P/E/G ratio of 2.09 and a beta of 1.10. The company has a fifty day moving average of $240.41 and a 200 day moving average of $276.45. Teleflex Incorporated has a 1 year low of $203.38 and a 1 year high of $391.39. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.27 and a quick ratio of 1.43.
Teleflex (NYSE:TFX – Get Rating) last posted its earnings results on Thursday, July 28th. The medical technology company reported $3.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.34 by $0.05. The company had revenue of $704.50 million during the quarter, compared to the consensus estimate of $719.50 million. Teleflex had a net
margin of 18.16% and a return on equity of 16.84%. The firm's quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the firm posted $3.35 earnings per share. Research analysts forecast that Teleflex Incorporated will post 13.12 earnings per share for the current year.
Teleflex Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Thursday, September 15th. Investors of record on Monday, August 15th were given a dividend of $0.34 per share. The ex-dividend date was Friday, August 12th. This represents a $1.36 dividend on an annualized basis and a yield of 0.66%. Teleflex's dividend payout ratio is presently 12.64%.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on the stock. Piper Sandler lowered their target price on shares of Teleflex from $295.00 to $265.00 in a research note on Thursday, July 28th. Morgan Stanley lowered their target price on shares of Teleflex from $300.00 to $278.00 and set an "equal weight" rating for the company in a research note on Friday, July 29th. StockNews.com downgraded shares of Teleflex from a "buy" rating to a "hold" rating in a research note on Friday, July 29th. Truist Financial lowered their target price on shares of Teleflex from $265.00 to $241.00 and set a "hold" rating for the company in a research note on Thursday. Finally, Wolfe Research started coverage on shares of Teleflex in a research note on Tuesday, July 5th. They set an "outperform" rating and a $300.00 price objective for the company. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $322.70.
About Teleflex
(Get Rating)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
See Also
- Get a free copy of the StockNews.com research report on Teleflex (TFX)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX – Get Rating).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.
